Kang Y, Balter B, Csizmadia E, Haas B, Sharma H, Bronson R, et al. Contribution of classical end-joining to PTEN inactivation in p53-mediated glioblastoma formation and drug-resistant survival. Nat Commun. 2017;8:14013 pubmed publisher

Kren B, Unger G, Abedin M, Vogel R, Henzler C, Ahmed K, et al. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy. Breast Cancer Res. 2015;17:19 pubmed publisher

Ahmed K, Kren B, Abedin M, Vogel R, Shaughnessy D, Nacusi L, et al. CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors. Oncotarget. 2016;7:61789-61805 pubmed publisher

Szabó A, Papin C, Zorn D, Ponien P, Weber F, Raabe T, et al. The CK2 kinase stabilizes CLOCK and represses its activity in the Drosophila circadian oscillator. PLoS Biol. 2013;11:e1001645 pubmed publisher

Trembley J, Unger G, Korman V, Tobolt D, Kazimierczuk Z, Pinna L, et al. Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. Cancer Lett. 2012;315:48-58 pubmed publisher

Hagan C, Regan T, Dressing G, Lange C. ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells. Mol Cell Biol. 2011;31:2439-52 pubmed publisher

Lee N, Iyer S, Mu J, Weissman J, Ohali A, Howcroft T, et al. Three novel downstream promoter elements regulate MHC class I promoter activity in mammalian cells. PLoS ONE. 2010;5:e15278 pubmed publisher

Pi J, Diwan B, Sun Y, Liu J, Qu W, He Y, et al. Arsenic-induced malignant transformation of human keratinocytes: involvement of Nrf2. Free Radic Biol Med. 2008;45:651-8 pubmed publisher

Pluemsampant S, Safronova O, Nakahama K, Morita I. Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors. Int J Cancer. 2008;122:333-41 pubmed